Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Telesis Bio Inc. TBIO

Healthcare  —  Medical Devices
0.00 (0.01) (100.00%) as of 25 Sep
Market cap
$5.3M
P/E
0.0×
Cash Flow Champion (3y) Revenue Champion (5y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Telesis Bio Inc. (TBIO) Business Profile

Updated before January 2025

Company Overview

Telesis Bio Inc. (TBIO), formerly known as Codex DNA, is a biotechnology company specializing in synthetic biology solutions. Founded in 2011 and headquartered in San Diego, California, TBIO has established itself as a leader in the field of DNA synthesis and genomic engineering. The company was co-founded by Dr. Daniel Gibson, a pioneer in synthetic biology, and has since grown under the leadership of its CEO, Todd R. Nelson. TBIO’s mission is to empower researchers and scientists with innovative tools to accelerate the development of synthetic biology applications, including therapeutics, vaccines, and diagnostics.

Core Business Segments

Synthetic Biology Solutions

TBIO’s primary focus is on providing advanced synthetic biology tools and platforms. The company’s flagship product, the BioXp™ system, is an automated benchtop platform that enables researchers to rapidly synthesize DNA, RNA, and proteins. This system is designed to streamline workflows and reduce the time required for molecular biology processes.

Key Products:

  • BioXp™ 9600 System: A fully automated platform for DNA assembly, cloning, and amplification.
  • BioXp™ Select Kits: Customizable kits for specific applications, such as gene synthesis and protein engineering.
  • Gibson Assembly® Kits: A proprietary technology for seamless DNA assembly, widely used in synthetic biology research.

Genomic Solutions

TBIO also offers a range of genomic tools and services to support research in areas such as gene editing, synthetic biology, and molecular diagnostics. These solutions are designed to enhance the accuracy and efficiency of genomic workflows.

Key Offerings:

  • Custom DNA and RNA Synthesis Services: Tailored solutions for researchers requiring specific genetic sequences.
  • Next-Generation Sequencing (NGS) Support: Tools and services to facilitate NGS workflows.

Biopharmaceutical Applications

TBIO’s technologies are increasingly being adopted in the biopharmaceutical industry for the development of novel therapeutics and vaccines. The company collaborates with leading pharmaceutical companies to accelerate drug discovery and development.

Business Model

TBIO operates on a hybrid business model that combines product sales, custom services, and licensing agreements. The company generates revenue through the sale of its BioXp™ systems, consumables, and proprietary kits. Additionally, TBIO offers custom DNA and RNA synthesis services, which provide a recurring revenue stream. Licensing agreements for its Gibson Assembly® technology further diversify its income sources. By integrating its products and services, TBIO aims to provide end-to-end solutions for its customers, fostering long-term partnerships and customer loyalty.

Strategic Direction

TBIO is focused on expanding its product portfolio and entering new markets to drive growth. Key strategic initiatives include:

  • Product Innovation: Developing next-generation BioXp™ systems with enhanced capabilities and broader applications.
  • Market Expansion: Targeting emerging markets in Asia-Pacific and Europe to increase global market share.
  • Sustainability Goals: Implementing eco-friendly practices in product development and manufacturing to reduce environmental impact.
  • Collaborations and Partnerships: Strengthening relationships with academic institutions, research organizations, and pharmaceutical companies to foster innovation.

Competitive Landscape

TBIO operates in a highly competitive market, facing competition from both established players and emerging startups. Key competitors include:

  • Twist Bioscience: A leader in synthetic DNA manufacturing.
  • Ginkgo Bioworks: Specializes in organism engineering and synthetic biology.
  • Thermo Fisher Scientific: Offers a wide range of genomic tools and services.
  • Integrated DNA Technologies (IDT): A major provider of custom DNA and RNA synthesis.

Despite the competition, TBIO differentiates itself through its proprietary technologies, such as the BioXp™ system and Gibson Assembly® kits, which offer unique advantages in terms of speed, accuracy, and automation.

Risk Factors

TBIO faces several risks that could impact its business operations and financial performance:

  • Market Dependence: Reliance on the synthetic biology market, which is subject to fluctuations in research funding and economic conditions.
  • Supply Chain Disruptions: Potential delays in the procurement of raw materials and components for its products.
  • Regulatory Challenges: Compliance with stringent regulations governing synthetic biology and genomic research.
  • Technological Obsolescence: The risk of competitors developing superior technologies.

Recent Developments

TBIO has made significant strides in recent years, including:

  • Launch of BioXp™ 9600 System: An upgraded version of its flagship platform with enhanced capabilities.
  • Partnerships with Pharmaceutical Companies: Collaborations to accelerate the development of mRNA-based vaccines and therapeutics.
  • Expansion into New Markets: Establishing a presence in Asia-Pacific and Europe to tap into growing demand for synthetic biology solutions.
  • Response to Global Challenges: Leveraging its technologies to support the development of COVID-19 diagnostics and vaccines.

Investment Considerations

Strengths:

  • Proprietary technologies with strong intellectual property protection.
  • Diversified revenue streams from product sales, services, and licensing.
  • Growing demand for synthetic biology solutions in research and biopharmaceuticals.
  • Strong leadership team with expertise in synthetic biology.

Risks:

  • High competition in the synthetic biology market.
  • Dependence on a limited number of key customers.
  • Potential regulatory hurdles and ethical concerns related to synthetic biology.

Conclusion

Telesis Bio Inc. is well-positioned to capitalize on the growing demand for synthetic biology solutions. With its innovative products, strong intellectual property portfolio, and strategic focus on market expansion, TBIO is poised for long-term growth. However, investors should carefully consider the risks associated with market competition and regulatory challenges. Overall, TBIO represents a compelling opportunity for those looking to invest in the rapidly evolving field of synthetic biology.